A Randomized, Double-Blind, Active- and Placebo- Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Active- and Placebo- Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs ABT 288 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
    • 19 Jul 2012 This trial was terminated for futility after 242 patients had been randomised according to the conference abstract
    • 19 Apr 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top